NO993804L - Farmasoeytiske blandinger av pinnsvin-proteiner og anvendelse derav - Google Patents

Farmasoeytiske blandinger av pinnsvin-proteiner og anvendelse derav

Info

Publication number
NO993804L
NO993804L NO993804A NO993804A NO993804L NO 993804 L NO993804 L NO 993804L NO 993804 A NO993804 A NO 993804A NO 993804 A NO993804 A NO 993804A NO 993804 L NO993804 L NO 993804L
Authority
NO
Norway
Prior art keywords
ions
hedgehog proteins
pharmaceutical mixtures
pharmaceutical
mixtures
Prior art date
Application number
NO993804A
Other languages
English (en)
Other versions
NO993804D0 (no
Inventor
Apollon Papadimitriou
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP98114851A external-priority patent/EP0987028A1/de
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of NO993804D0 publication Critical patent/NO993804D0/no
Publication of NO993804L publication Critical patent/NO993804L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Detergent Compositions (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

En blanding av et pinnsvin-protein som inneholder, som additiv, sinkioner, magnesiumioner, kalsiumioner, sulfationer, cyklodekstrin, et ikke-ionisk overflateaktivt middel og/eller et anionisk sakkarid, er spesielt stabil ved romtemperatur.
NO993804A 1998-08-07 1999-08-06 Farmasoeytiske blandinger av pinnsvin-proteiner og anvendelse derav NO993804L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP98114851A EP0987028A1 (de) 1998-08-07 1998-08-07 Pharmazeutische Zusammensetzung von Hedgehog-Proteinen und deren Verwendung
EP98116734 1998-09-03

Publications (2)

Publication Number Publication Date
NO993804D0 NO993804D0 (no) 1999-08-06
NO993804L true NO993804L (no) 2000-02-08

Family

ID=26149508

Family Applications (1)

Application Number Title Priority Date Filing Date
NO993804A NO993804L (no) 1998-08-07 1999-08-06 Farmasoeytiske blandinger av pinnsvin-proteiner og anvendelse derav

Country Status (15)

Country Link
US (1) US6207718B1 (no)
EP (1) EP0978285B1 (no)
JP (1) JP3567103B2 (no)
CN (1) CN1244429A (no)
AT (1) ATE310531T1 (no)
AU (1) AU761341B2 (no)
CA (1) CA2279743C (no)
DE (1) DE69928472T2 (no)
DK (1) DK0978285T3 (no)
ES (1) ES2253851T3 (no)
HK (1) HK1025740A1 (no)
HU (1) HUP9902655A3 (no)
IL (1) IL131238A (no)
MA (1) MA26667A1 (no)
NO (1) NO993804L (no)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL136230A0 (en) * 1997-11-28 2001-05-20 Roche Diagnostics Gmbh An active hedgehog-protein-mutant, a process for its preparation and its use for pharmaceutical purposes
US6897297B1 (en) * 1997-12-03 2005-05-24 Curis, Inc. Hydrophobically-modified protein compositions and methods
DK0953576T3 (da) * 1998-04-30 2006-03-20 Curis Inc Aktivt hedgehog-proteinkonjugat, fremgangsmåde til fremstilling heraf og anvendelse
EP1025861A1 (de) * 1999-02-04 2000-08-09 Roche Diagnostics GmbH Pharmazeutische Zusammensetzung von hydrophob modifizierten Hedgehog-Proteinen und deren Verwendung
US20040220103A1 (en) * 1999-04-19 2004-11-04 Immunex Corporation Soluble tumor necrosis factor receptor treatment of medical disorders
CA2280925A1 (en) * 1999-07-29 2001-01-29 Bernard Charles Sherman Stabilized cefuroxime axetil
AU2001255767A1 (en) 2000-04-28 2001-11-12 Curis, Inc. Methods and reagents for tissue engineering of cartilage in vitro
EP1947116B1 (en) 2003-02-10 2017-06-21 2-BBB Medicines B.V. Differentially expressed nucleic acids in the blood-brain barrier under inflammatory conditions
US20070053883A1 (en) * 2003-03-25 2007-03-08 The Johns Hopkins University Neuronal cell lineages and methods of production thereof
US20070148144A1 (en) * 2005-10-27 2007-06-28 Mason James M Gene-enhanced tissue engineering
AU2007234612B2 (en) 2006-12-14 2013-06-27 Johnson & Johnson Regenerative Therapeutics, Llc Protein stabilization formulations
PT2308514E (pt) 2007-03-23 2013-09-06 To Bbb Holding B V Conjugados para a administração orientada de medicamentos através da barreira hematoencefálica
ATE494001T1 (de) * 2007-06-29 2011-01-15 Atrm Llc Flüssige proteinformulierungen mit gdf-5 zur verwendung bei erhöhten temperaturen
US7678764B2 (en) * 2007-06-29 2010-03-16 Johnson & Johnson Regenerative Therapeutics, Llc Protein formulations for use at elevated temperatures
US8058237B2 (en) * 2007-08-07 2011-11-15 Advanced Technologies & Regenerative Medicine, LLC Stable composition of GDF-5 and method of storage
CN102026619A (zh) * 2008-04-14 2011-04-20 先进科技及再生医学有限责任公司 液体缓冲的gdf-5制剂
WO2010087702A1 (en) 2009-01-30 2010-08-05 Stichting Katholieke Universiteit TET2 gene as a marker for diagnosing a myelodysuplastic syndrome (MDS) or an acute myeloid leukemia (AML) and determining the prognosis in a subject
WO2011034421A1 (en) 2009-09-16 2011-03-24 Stichting Het Nederlands Kanker Instituut Fra-1 target genes as drug targets for treating cancer
EP2305717A1 (en) 2009-09-21 2011-04-06 Koninklijke Nederlandse Akademie van Wetenschappen Inhibiting TNIK for treating colon cancer
WO2012026820A2 (en) 2010-08-27 2012-03-01 Pantarhei Bioscience B.V. Immunotherapeutic method for treating prostate cancer
EP2465928A1 (en) 2010-12-16 2012-06-20 Academisch Medisch Centrum bij de Universiteit van Amsterdam Treatment of Th17-mediated diseases
EP3065829B1 (en) 2013-11-08 2021-05-19 University of Virginia Patent Foundation Compositions and methods for treating melanoma
WO2016080830A2 (en) 2014-11-18 2016-05-26 Pantarhei Bioscience B.V. Immunotherapeutic method for treating pancreatic cancer
CA3043886A1 (en) * 2016-11-16 2018-05-24 Aivita Biomedical, Inc. Use of cell membrane-bound signaling factors
NZ764440A (en) * 2017-11-16 2024-03-22 Aivita Biomedical Inc Use of cell membrane-bound signaling factors

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2148901A (en) 1983-10-04 1985-06-05 Johnson & Johnson Protein/polysaccharide complexes
JPH0725689B2 (ja) 1986-10-07 1995-03-22 中外製薬株式会社 顆粒球コロニ−刺激因子を含有する徐放性製剤
US5078997A (en) 1988-07-13 1992-01-07 Cetus Corporation Pharmaceutical composition for interleukin-2 containing physiologically compatible stabilizers
US5007790A (en) 1989-04-11 1991-04-16 Depomed Systems, Inc. Sustained-release oral drug dosage form
US5156623A (en) 1990-04-16 1992-10-20 Olympus Optical Co., Ltd. Sustained release material and method of manufacturing the same
US5416071A (en) 1991-03-12 1995-05-16 Takeda Chemical Industries, Ltd. Water-soluble composition for sustained-release containing epo and hyaluronic acid
DE4126983A1 (de) 1991-08-15 1993-02-18 Boehringer Mannheim Gmbh Verfahren zur herstellung von humanprotein-enthaltenden, konservierten arzneimitteln fuer infusions- oder injektionszwecke
US5215758A (en) 1991-09-11 1993-06-01 Euroceltique, S.A. Controlled release matrix suppository for pharmaceuticals
US5789543A (en) 1993-12-30 1998-08-04 President And Fellows Of Harvard College Vertebrate embryonic pattern-inducing proteins and uses related thereto
NZ278765A (en) 1993-12-30 1998-05-27 Harvard College Vertebrate proteins involved in spatial arrangements of differentiated tissues called hedgehog proteins, their production and use
JPH09509574A (ja) * 1994-02-25 1997-09-30 ザ・トラスティーズ・オブ・コランビア・ユニバーシティー・イン・ザ・シティー・オブ・ニューヨーク 脊索によって発現されるヘッジホッグ、Ｖｈｈ−１、の脊椎動物相同体をコードするＤＮＡ、及びこれらの使用
US5663390A (en) 1996-08-29 1997-09-02 Libbey-Owens-Ford Co. Method of producing organo indium chlorides
JPH10194987A (ja) 1997-01-14 1998-07-28 Youtai Iwamoto 骨・軟骨形成用組成物
US6656508B2 (en) 1997-04-17 2003-12-02 Amgen Inc. Sustained-release alginate gels
EP0947201B1 (en) 1998-02-04 2006-06-28 Curis, Inc. Pharmaceutical composition of hedgehog proteins and use thereof
DK0953576T3 (da) 1998-04-30 2006-03-20 Curis Inc Aktivt hedgehog-proteinkonjugat, fremgangsmåde til fremstilling heraf og anvendelse
EP0953575A1 (de) 1998-04-30 1999-11-03 Boehringer Mannheim Gmbh Aktives Hedgehog-Protein-Konjugat, Verfahren zur Herstellung und Verwendung

Also Published As

Publication number Publication date
ES2253851T3 (es) 2006-06-01
CA2279743C (en) 2005-05-10
HUP9902655A2 (hu) 2000-08-28
AU761341B2 (en) 2003-06-05
JP2000063283A (ja) 2000-02-29
DE69928472T2 (de) 2006-08-10
JP3567103B2 (ja) 2004-09-22
MA26667A1 (fr) 2004-12-20
US6207718B1 (en) 2001-03-27
HK1025740A1 (en) 2000-11-24
EP0978285A1 (en) 2000-02-09
HU9902655D0 (en) 1999-10-28
EP0978285B1 (en) 2005-11-23
CN1244429A (zh) 2000-02-16
IL131238A0 (en) 2001-01-28
ATE310531T1 (de) 2005-12-15
AU4344899A (en) 2000-03-02
DE69928472D1 (de) 2005-12-29
NO993804D0 (no) 1999-08-06
HUP9902655A3 (en) 2000-12-28
CA2279743A1 (en) 2000-02-07
IL131238A (en) 2005-07-25
DK0978285T3 (da) 2006-03-27

Similar Documents

Publication Publication Date Title
NO993804L (no) Farmasoeytiske blandinger av pinnsvin-proteiner og anvendelse derav
Earnshaw Nuclear changes in apoptosis
DK1028741T3 (da) Regulering af epitelvæv ved hjælp af hedgehog-lignende polypeptider og formuleringer og anvendelser, som er relateret hertil
BR0202278A (pt) Dispositivos e processos para a colheita de células
BR0017013A (pt) Composições de antibiótico azalìdeo
NO20005421L (no) Stabile oksiderende brom formuleringer, fremgangsmåter ved fremstilling derav og fremgangsmåter ved anvendelse for mikrobiologisk vekst kontroll
BR9814104A (pt) Compostos benzeno substituìdos, processo parasua preparação e composições herbicidas edesfolhantes contendo os mesmos
BG99261A (en) Steroid glycosides for the treatment of hyperchlesterolemia
ECSP034442A (es) Mezclas de polisacaridos derivados de la heparina, su preparacion y las composiciones farmaceuticas que las contienen
AU7400791A (en) Enzyme stabilizing composition and stabilized enzyme containing built detergent compositions
BR9910920A (pt) Composição não inflamável, e, processos de limpeza e de revestimento
AU2003259789A1 (en) High concentration surfactant compositions and methods
HK1047032A1 (zh) 處理解開的蛋白質表現方法的方法及產品
BR0116408A (pt) Composições de fermento lìquido
NO953644L (no) Konsentrerte rengjöringsblandinger
MX9305354A (es) Detergente liquido o en forma de gel para el lavado de vajilla que contiene alquil etoxi carboxilato, iones divalentes y alquilpolietoxipolicarboxilato.
KR860000025A (ko) 콩단백질 수용액의 처리방법
BR9808140A (pt) Formulação unitária
PT1411971E (pt) Utilizacao de pentraxina longa ptx3 para o tratamento de infertilidade feminina
DK0943030T3 (da) Fremgangsmåde til reduktion af svovl- og kypefarvestoffer
NO20002525D0 (no) Blanding anvendelig som overflateaktivt emulgeringsmiddel og dispersjon, fremgangsmÕte for fremstilling derav samt dets anvendelse
DK0497724T3 (da) Middel til desintegration af galdesten
AU2001265876A1 (en) Novel use of pulmonary surfactant for the prophylaxis or early treatment of acute pulmonary diseases
TR199901897A2 (xx) İspençiyari kirpi proteinleri terkibi ve bunun kullanılması.
GR1003060B (el) Συστημα εγκαιρης κατασβεσης δασικων πυρκαγιων, εθνικων δρυμων, ζοωλογικων κηπων κλπ

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application